This article, Infections Post-inequalities: Realizing the End of Tuberculosis Through Equitable Economic Orders, explores TB as a proxy metric for the failure to dismantle colonial structures in global health and to realize the rights to health and science. Fundamentally, the…
Treatment Action Group (TAG) welcomes the introduction of the House companion to the Cure Hepatitis C Act (S.1941) and applauds Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Hank Johnson (D-GA), and Don Bacon (R-NE) for advancing bipartisan legislation to eliminate hepatitis C in the United States. We are particularly encouraged that the House bill removes the immigration-based eligibility restrictions contained in Section 10 of the Senate version — an important improvement that brings the legislation closer to the public health principles necessary to achieve hepatitis C virus (HCV) elimination in the United States in our lifetimes.
Treatment Action Group (TAG) has submitted formal comments opposing a proposed rule from the White House Office of Management and Budget (OMB) that would overhaul how federal research grants are awarded and managed. Under the proposed rule changes, scientific experts would still review research applications, but political appointees would have final authority to approve, deny, or cancel awards based on alignment with the administration's priorities.
The United States is currently at an inflection point in Hepatitis C virus (HCV) response. We have the tools for rapid and accurate diagnosis, safe and effective cure, and prevention. These tools are only as useful as access to them can be, which is why the Cure Hepatitis C Act (S.1941) holds so much promise.
TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.
Treatment Action Group (TAG) is profoundly troubled by recent reporting that the NIH’s longstanding Notice of Funding Opportunity (NOFO) process is being interrupted and delayed by political interference.
TAG condemns the United States’ war in Iran and neighboring countries. At a time when U.S. investment in public health is being slashed, the Trump administration has chosen to spend billions of dollars per day on weapons used in a war of choice for which no credible rationale has been proposed. Our government should invest in our communities by spending funds that were already appropriated and illegally impounded by the White House Office of Management and Budget to keep people healthy, rather than starting new wars that put the entire world’s health at risk.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
Behind many lifesaving vaccines is a fragile supply chain that few people ever see. This new TAG report examines how weaknesses in the production and supply of key vaccine adjuvants (an ingredient that enhances the immune response) can create bottlenecks that threaten global access to vaccines, underscoring the importance of greater market transparency, security, and competitiveness among governments, funders, and pharmaceutical companies.
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first of its kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines.